APTX

NYX-458

Parkinson's Disease Cognitive Impairment

Phase 2 to be initiated

Exp Date

Q1 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: NYX-458 for Parkinson's Disease Cognitive Impairment  Phase 2 to be initiated

  • Clinical Trial (NCT04148391) A Study to Evaluate NYX-458 in Subjects With PD-MCI


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 to be initiated


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q1 2021


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION

  • Approximately half of all people with Parkinson’s suffer from cognitive impairment

  • It is believed that the loss of dopaminergic neurons and the associated downstream changes including dysregulation and dysfunction of NMDA receptors, leads to impairments across multiple cognitive domains

  • NYX-458 has the potential to treat these cognitive symptoms by modulating NMDA receptor function to overcome the dysregulation caused by the loss of dopaminergic neurons

Updated by MV

NYX-458, NMDA receptor, Parkinson's Disease, mental illness, APTX, Aptinyx

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon